---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-038742"
form_type: "8-K"
ticker: "TNGX"
cik: "0001819133"
company_name: "Tango Therapeutics, Inc."
filed_at: "2023-08-07T23:59:59+00:00"
generated_at: "2026-06-12T04:43:19.696028+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tango doses first patients in TNG462, TNG260 trials; CSO Alan Huang to depart; Q2 net loss narrows

## Summary
- First patient dosed in phase 1/2 of TNG462 (next-gen PRMT5 inhibitor) for MTAP-deleted tumors.
- First patient dosed in phase 1/2 of TNG260 (CoREST inhibitor) with pembrolizumab for STK11-mutant cancers.
- CSO Alan Huang to step down Oct 2023; Jannik Andersen promoted to CSO effective Oct 9, 2023.
- Cash $310.7M as of June 30, 2023, sufficient to fund operations into 2026.
- Q2 2023 net loss $20.7M ($0.23/sh) vs $24.9M ($0.28/sh) in Q2 2022; license revenue $5.0M from Gilead.

## SEC filing metadata
- accession: 0000950170-23-038742
- form_type: 8-K
- ticker: TNGX
- cik: 0001819133
- company_name: Tango Therapeutics, Inc.
- filed_at: 2023-08-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819133/000095017023038742/0000950170-23-038742-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819133/000095017023038742/tngx-20220810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-038742
- JSON: https://secwatch.observer/filing/0000950170-23-038742.json
- Plain text: https://secwatch.observer/filing/0000950170-23-038742.txt

## Key facts
- Earnings Releases
  Tango Therapeutics, Inc. reported financial results for second quarter ended June 30, 2023.
  - Period: second quarter ended June 30, 2023
  - Result: reported results
  source text: On August 7, 2023, Tango Therapeutics, Inc. (Tango or the Company) issued a press release relating to its results of operations and financial condition for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819133/000095017023038742/0000950170-23-038742-index.htm
- Executive change
  Alan Huang changed role as Chief Scientific Officer at Tango Therapeutics, Inc..
  - Action: transition out
  - Role: Chief Scientific Officer
  source text: On August 3, 2023, Alan Huang, Ph.D., the Company's Chief Scientific Officer, notified the Company that he intends to transition out of his role as Chief Scientific Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819133/000095017023038742/0000950170-23-038742-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.